Cardionovum

Be up
to date.

Latest press release

RESTORE® Drug-Coated Balloon receives first Chinese FDA medical device registration certificate for two indications

RESTORE®, CARDIONOVUM’s innovative paclitaxel-coated balloon for coronary applications has received market approval for China, making it the first drug-coated balloon (DCB) available in China to treat two indications: in-stent restenosis (ISR) and small vessel disease (SVD). The approval was given based on the impressive results from two solidly designed clinical studies in Chinese populations: RESTORE ISR CHINA and RESTORE SVD CHINA.

Learn more >>

J.C. van den Berg discusses results from the APERTO AVF study

Learn more >>

Koen Deloose discusses final results from the Reflow trial

Learn more >>

Matteo Tozzi discusses new data from the APERTO AVF study

Learn more >>

Dr. Bosier interview at LINC 2019

Learn more >>

CARDIONOVUM Press Release: RESTORE® Drug-Coated Balloon Matches Zotarolimus-Eluting Stent in Patients with Coronary Small Vessel Lesions

Learn more >>

Upcoming events

Cardionovum® at GISE 2024

Cardionovum® is pleased to invite you to visit us at booth #43.

Location:

Allianz MiCo - Milano Congressi
South Wing
Viale Eginardo - Gate 2
20149 Milano
Italy

Date: Nov 19, 2024–Nov 23, 2024

Latest events

CARDIONOVUM GmbH at IAD

Cardionovum participates in:
9th Annual IAD Conference Interdisciplinary Working Group on Dialysis Access.

We invite you to visit us at booth #7.

Location: Weimar, Germany

Date: Nov 19, 2021–Nov 21, 2021

Cardionovum at CIRSE 2021

Cardionovum invites you to participate in 3 scientific presentations in the "Technology Innovations Videos":

  • Sunday 26th
    The SAFEPAX Technology presented by Dr. Michael Lichtenberg.

  • Monday 27th
    The Reflow Study at 2 years follow up. by Dr. Marc Bosiers.

  • Tuesday 28th
    Clinical outcomes with APERTO Balloon. by Dr. Matteo Tozzi.

Date: Sep 25, 2021–Sep 29, 2021

Learn more >>

Cardionovum at EuroPCR 18, 19, 20 May 2021

Cardionovum invites you to participate in on demand interviwes:

  • XLIMIT Trial RCT, with Dr. Luca Testa from Italy.
    Goal: to assess angiographic and clinical performance of the Xlimus Biodegradable Polymer Sirolumus-eluting stent versus a gold standard like Synergy Biodegradable Polymer Everolimus Stent in patients treated with percutaneous coronary angioplasty.

  • Hyper Registry with Dr. Alfonso Ileasi from Italy.
    Goal: Asses the clinical results after a Hybrid Approach in diffuse CAD lesions longer tan 28mm combinig Restore DCB and New generation DES.

Date: May 18, 2021–May 21, 2021

Learn more >>

go top